The role of genetic testing in diagnosis and care of inherited cardiac conditions in a specialised multidisciplinary clinic
Background The diagnostic yield of genetic testing for inherited cardiac diseases is up to 40% and is primarily indicated for screening of at-risk relatives. Here, we evaluate the role of genomics in diagnosis and management among consecutive individuals attending a specialised clinic and identify those with the highest likelihood of having a monogenic disease. Methods A retrospective audit of 1697 consecutive, unrelated probands referred to a specialised, multidisciplinary clinic between 2002 and 2020 was performed. A concordant clinical and genetic diagnosis was considered solved. Cases were classified as likely monogenic based on a score comprising a positive family history, young age at onset, and severe phenotype, whereas low-scoring cases were considered to have a likely complex aetiology. The impact of a genetic diagnosis was evaluated. Results A total of 888 probands fulfilled the inclusion criteria, and genetic testing identified likely pathogenic or pathogenic (LP/P) variants in 330 individuals (37%) and suspicious variants of uncertain significance (VUS) in 73 (8%). Research-focused efforts identified 46 (5%) variants, missed by conventional genetic testing. Where a variant was identified, this changed or clarified the final diagnosis in a clinically useful way for 51 (13%). The yield of suspicious VUS across ancestry groups ranged from 15 to 20%, compared to only 10% among Europeans. Even when the clinical diagnosis was uncertain, those with the most monogenic disease features had the greatest diagnostic yield from genetic testing. Conclusions Research-focused efforts can increase the diagnostic yield by up to 5%. Where a variant is identified, this will have clinical utility beyond family screening in 13%. We demonstrate the value of genomics in reaching an overall diagnosis and highlight inequities based on ancestry. Acknowledging our incomplete understanding of disease phenotypes, we propose a framework for prioritising likely monogenic cases to solve their underlying cause of disease..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Genome medicine - 14(2022), 1 vom: 28. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stafford, Fergus [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Genetic testing |
|---|
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1186/s13073-022-01149-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR051271443 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR051271443 | ||
| 003 | DE-627 | ||
| 005 | 20230509123404.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230508s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13073-022-01149-0 |2 doi | |
| 035 | |a (DE-627)SPR051271443 | ||
| 035 | |a (SPR)s13073-022-01149-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stafford, Fergus |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of genetic testing in diagnosis and care of inherited cardiac conditions in a specialised multidisciplinary clinic |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Background The diagnostic yield of genetic testing for inherited cardiac diseases is up to 40% and is primarily indicated for screening of at-risk relatives. Here, we evaluate the role of genomics in diagnosis and management among consecutive individuals attending a specialised clinic and identify those with the highest likelihood of having a monogenic disease. Methods A retrospective audit of 1697 consecutive, unrelated probands referred to a specialised, multidisciplinary clinic between 2002 and 2020 was performed. A concordant clinical and genetic diagnosis was considered solved. Cases were classified as likely monogenic based on a score comprising a positive family history, young age at onset, and severe phenotype, whereas low-scoring cases were considered to have a likely complex aetiology. The impact of a genetic diagnosis was evaluated. Results A total of 888 probands fulfilled the inclusion criteria, and genetic testing identified likely pathogenic or pathogenic (LP/P) variants in 330 individuals (37%) and suspicious variants of uncertain significance (VUS) in 73 (8%). Research-focused efforts identified 46 (5%) variants, missed by conventional genetic testing. Where a variant was identified, this changed or clarified the final diagnosis in a clinically useful way for 51 (13%). The yield of suspicious VUS across ancestry groups ranged from 15 to 20%, compared to only 10% among Europeans. Even when the clinical diagnosis was uncertain, those with the most monogenic disease features had the greatest diagnostic yield from genetic testing. Conclusions Research-focused efforts can increase the diagnostic yield by up to 5%. Where a variant is identified, this will have clinical utility beyond family screening in 13%. We demonstrate the value of genomics in reaching an overall diagnosis and highlight inequities based on ancestry. Acknowledging our incomplete understanding of disease phenotypes, we propose a framework for prioritising likely monogenic cases to solve their underlying cause of disease. | ||
| 650 | 4 | |a Inherited cardiac conditions |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Sudden cardiac death |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Genetic testing |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Krishnan, Neesha |4 aut | |
| 700 | 1 | |a Richardson, Ebony |4 aut | |
| 700 | 1 | |a Butters, Alexandra |4 aut | |
| 700 | 1 | |a Hespe, Sophie |4 aut | |
| 700 | 1 | |a Burns, Charlotte |4 aut | |
| 700 | 1 | |a Gray, Belinda |4 aut | |
| 700 | 1 | |a Medi, Caroline |4 aut | |
| 700 | 1 | |a Nowak, Natalie |4 aut | |
| 700 | 1 | |a Isbister, Julia C. |4 aut | |
| 700 | 1 | |a Raju, Hariharan |4 aut | |
| 700 | 1 | |a Richmond, David |4 aut | |
| 700 | 1 | |a Ryan, Mark P. |4 aut | |
| 700 | 1 | |a Singer, Emma S. |4 aut | |
| 700 | 1 | |a Sy, Raymond W. |4 aut | |
| 700 | 1 | |a Yeates, Laura |4 aut | |
| 700 | 1 | |a Bagnall, Richard D. |4 aut | |
| 700 | 1 | |a Semsarian, Christopher |4 aut | |
| 700 | 1 | |a Ingles, Jodie |0 (orcid)0000-0002-4846-7676 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Genome medicine |d London : BioMed Central, 2009 |g 14(2022), 1 vom: 28. Dez. |w (DE-627)SPR030550335 |w (DE-600)2484394-5 |x 1756-994X |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:1 |g day:28 |g month:12 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13073-022-01149-0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 1 |b 28 |c 12 | ||